By its design, MM-111 blocks the activity of ligand-dependent and ligand-independent ErbB2/ErbB3 complexes in tumor cells, hence, recapitulating the effect of combining trastuzumab and pertuzumab or lapatanib, albeit in a completely different manner. The gene discussed is ERBB3; the disease is neoplasm.